Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. (September 2017)

• Record Type: Journal Article
• Authors: Ives, Natalie J.; Suciu, Stefan; Eggermont, Alexander M.M.; Kirkwood, John; Lorigan, Paul; Markovic, Svetomir N.; Garbe, Claus; Wheatley, Keith
• Is Part Of: European journal of cancer. Volume 82(2017)
• Page Start: 171
• Page End: 183
• Publication Date: 2017-09
• Subjects: Individual patient data meta-analysis -- Randomised controlled trials -- Melanoma -- Adjuvant interferon; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.06.006
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Many randomised trials assessing interferon-α (IFN-α) as adjuvant therapy for high-risk malignant melanoma have been undertaken. To better assess the role of IFN-α, an individual patient data (IPD) meta-analysis of these trials was undertaken. Methods: IPD was sought from all randomised trials of adjuvant IFN-α versus no IFN-α for high-risk melanoma. Primary outcomes were event-free survival (EFS) and overall survival (OS). Standard methods for quantitative IPD meta-analysis were used. Subgroup analyses by dose, duration of treatment and various patient and disease-specific parameters were performed. Findings: Fifteen trials were included in the analysis (eleven with IPD). EFS was significantly improved with IFN-α (hazard ratio [HR] = 0.86, CI 0.81–0.91; P < 0.00001), as was OS (HR = 0.90, CI 0.85–0.97; P = 0.003). The absolute differences in EFS at 5 and 10 years were 3.5% and 2.7%, and for OS were 3.0% and 2.8% respectively in favour of IFN-α. There was no evidence that the benefit of IFN-α differed depending on dose or duration of treatment, or by age, gender, site of primary tumour, disease stage, Breslow thickness, or presence of clinical nodes. Only for ulceration was there evidence of an interaction (test for heterogeneity: P = 0.04 for EFS; P = 0.002 for OS); only patients with ulcerated tumours appeared to obtain benefit from IFN-α. Conclusion: This meta-analysis provides clear evidence that adjuvant IFN-α significantly reduces the risk of relapse and improves survival and shows no benefit for higher doses compared to lower doses. The increased benefit in patients with ulcerated tumours, and lack of benefit in patients without ulceration, needs further investigation. Highlights: Adjuvant IFN-α significantly reduces the risk of relapse and improves overall survival. There was no evidence of a difference between higher and lower doses of adjuvant IFN-α. There was no evidence that the benefit of IFN-α differed in different patient types, except for ulceration. The finding that ulceration may be predictive of response to IFN-α needs confirmation in appropriately designed prospective studies.